Literature DB >> 8298979

Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease.

A Harley1, J M Cooper, A H Schapira.   

Abstract

Inactivation of the mitochondrial respiratory chain in response to iron-induced oxidative stress has been studied in cultured cells. Iron loading resulted in malonaldehyde production, decreased levels of glutathione and reduced specific activities of both complexes I and IV of the respiratory chain. These results are discussed with respect to idiopathic Parkinson's disease, which is associated with increased iron levels and a specific decrease in complex I activity in the substantia nigra.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298979     DOI: 10.1016/0006-8993(93)90341-j

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  p53-independent inhibition of proliferation and p21(WAF1/Cip1)-modulated induction of cell death by the antioxidants N-acetylcysteine and vitamin E.

Authors:  J L Nargi; R R Ratan; D E Griffin
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

Review 3.  Mitochondrial dysfunction in neurodegeneration.

Authors:  J M Cooper; A H Schapira
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

4.  Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency.

Authors:  R Rafique; A H Schapira; J M Cooper
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

5.  Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin.

Authors:  K Zaman; H Ryu; D Hall; K O'Donovan; K I Lin; M P Miller; J C Marquis; J M Baraban; G L Semenza; R R Ratan
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

6.  A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy.

Authors:  S Rahman; J W Taanman; J M Cooper; I Nelson; I Hargreaves; B Meunier; M G Hanna; J J García; R A Capaldi; B D Lake; J V Leonard; A H Schapira
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

7.  Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine-induced dopaminergic cell damage: implication for neuroprotection in Parkinson's disease.

Authors:  Zhen-Hua Shi; Guangjun Nie; Xiang-Lin Duan; Tracey Rouault; Wen-Shuang Wu; Bo Ning; Nan Zhang; Yan-Zhong Chang; Bao-Lu Zhao
Journal:  Antioxid Redox Signal       Date:  2010-09-15       Impact factor: 8.401

8.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

Review 9.  Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies.

Authors:  Emilio Fernandez-Espejo
Journal:  Mol Neurobiol       Date:  2004-02       Impact factor: 5.590

10.  Thiol agents and Bcl-2 identify an alphavirus-induced apoptotic pathway that requires activation of the transcription factor NF-kappa B.

Authors:  K I Lin; S H Lee; R Narayanan; J M Baraban; J M Hardwick; R R Ratan
Journal:  J Cell Biol       Date:  1995-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.